These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1703436)

  • 1. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.
    Ehrlich HJ; Keijer J; Preissner KT; Gebbink RK; Pannekoek H
    Biochemistry; 1991 Jan; 30(4):1021-8. PubMed ID: 1703436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
    Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
    Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.
    Ehrlich HJ; Gebbink RK; Preissner KT; Keijer J; Esmon NL; Mertens K; Pannekoek H
    J Cell Biol; 1991 Dec; 115(6):1773-81. PubMed ID: 1721912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin.
    Ehrlich HJ; Gebbink RK; Keijer J; Pannekoek H
    J Biol Chem; 1992 Jun; 267(16):11606-11. PubMed ID: 1375944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
    Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
    J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
    Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
    J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
    Ehrlich HJ; Gebbink RK; Keijer J; Linders M; Preissner KT; Pannekoek H
    J Biol Chem; 1990 Aug; 265(22):13029-35. PubMed ID: 1695900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
    Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
    J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin.
    Seiffert D; Loskutoff DJ
    Biochim Biophys Acta; 1991 May; 1078(1):23-30. PubMed ID: 1710930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2.
    Stefansson S; Lawrence DA; Argraves WS
    J Biol Chem; 1996 Apr; 271(14):8215-20. PubMed ID: 8626514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin.
    Wun TC; Palmier MO; Siegel NR; Smith CE
    J Biol Chem; 1989 May; 264(14):7862-8. PubMed ID: 2470735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a).
    Edelberg JM; Reilly CF; Pizzo SV
    J Biol Chem; 1991 Apr; 266(12):7488-93. PubMed ID: 1708387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.
    Seiffert D; Mimuro J; Schleef RR; Loskutoff DJ
    Cell Differ Dev; 1990 Dec; 32(3):287-92. PubMed ID: 1711915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants.
    Lawrence DA; Strandberg L; Ericson J; Ny T
    J Biol Chem; 1990 Nov; 265(33):20293-301. PubMed ID: 1700786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells.
    Mimuro J; Loskutoff DJ
    J Biol Chem; 1989 Mar; 264(9):5058-63. PubMed ID: 2494180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators.
    Takeuchi T; Niiya K; Kubonishi I; Miyoshi I
    Thromb Haemost; 1990 Apr; 63(2):259-64. PubMed ID: 2363126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of multiple types of plasminogen activator inhibitors from vascular smooth muscle cells.
    Laug WE; Aebersold R; Jong A; Rideout W; Bergman BL; Baker J
    Thromb Haemost; 1989 Jun; 61(3):517-21. PubMed ID: 2799763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1.
    Chain D; Kreizman T; Shapira H; Shaltiel S
    FEBS Lett; 1991 Jul; 285(2):251-6. PubMed ID: 1713175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin.
    Seiffert D; Loskutoff DJ
    J Biol Chem; 1991 Feb; 266(5):2824-30. PubMed ID: 1704366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.